| |
CoC-Group (N = 251)
|
non-CoC-Group (N = 110)
|
|---|
|
Median age, years (range; interquartile range)
|
63 (30–83; 56.1–68.7)
|
65 (40–86; 56.4–71.5)
|
|
Sex
|
|
Male
|
164 (65%)
|
77 (70%)
|
|
Female
|
87 (35%)
|
33 (30%)
|
|
WHO status
|
|
0
|
139 (55%)
|
63 (57%)
|
|
1
|
90 (36%)
|
40 (36%)
|
|
2
|
2 (1%)
|
2 (2%)
|
|
Missing data
|
20 (8%)
|
5 (5%)
|
|
Therapy arm
| | |
|
Capecitabine
|
127 (51%)
|
53 (48%)
|
|
5-FU
|
124 (49%)
|
57 (52%)
|
|
Cohort
|
|
Adjuvant
|
182 (73%)
|
36 (33%)
|
|
Neoadjuvant
|
69 (27%)
|
74 (67%)
|
|
Tumour categorya
|
|
T1 or T2
|
48 (19%)
|
12 (11%)
|
|
T3
|
184 (73%)
|
89 (81%)
|
|
T4
|
18 (7%)
|
8 (7%)
|
|
Missing data
|
1 (< 1%)
|
1 (1%)
|
|
Nodal categorya
|
|
Node negative
|
93 (37%)
|
45 (41%)
|
|
Node positive
|
157 (63%)
|
60 (54%)
|
|
Missing data
|
1 (< 1%)
|
5 (5%)
|
- Data are n (%) or median (range). aclinical or pathological category. WHO World Health Organization, FU fluorouracil. T - size or direct extent of the primary tumor
